These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20649824)
1. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824 [TBL] [Abstract][Full Text] [Related]
2. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133 [TBL] [Abstract][Full Text] [Related]
3. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM; Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib for the treatment of advanced renal cell carcinoma. Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060 [TBL] [Abstract][Full Text] [Related]
9. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013 [TBL] [Abstract][Full Text] [Related]
10. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442 [TBL] [Abstract][Full Text] [Related]
11. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Amato R; Zhai J; Willis J; Saxena S; DeFoe M Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785 [TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Riechelmann RP; Chin S; Wang L; Tannock IF; Berthold DR; Moore MJ; Knox JJ Am J Clin Oncol; 2008 Apr; 31(2):182-7. PubMed ID: 18391604 [TBL] [Abstract][Full Text] [Related]
15. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Kawashima A; Takayama H; Arai Y; Tanigawa G; Nin M; Kajikawa J; Imazu T; Kinoshita T; Yasunaga Y; Inoue H; Nishimura K; Takada S; Nishimura K; Tsujimura A; Nonomura N; Eur J Cancer; 2011 Jul; 47(10):1521-6. PubMed ID: 21550799 [TBL] [Abstract][Full Text] [Related]
16. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. Mancuso A; Di Paola ED; Leone A; Catalano A; CalabrĂ² F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284 [TBL] [Abstract][Full Text] [Related]
17. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055 [TBL] [Abstract][Full Text] [Related]
18. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261 [TBL] [Abstract][Full Text] [Related]
19. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711 [TBL] [Abstract][Full Text] [Related]
20. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]